Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) Stock Price

Laboratorios Rovi, formally Laboratorios Farmacéuticos ROVI, S.A., is a pharmaceutical company founded in 1946 and registered in Madrid. Its official website presents it as a specialised pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Its shares are traded on the Madrid, Barcelona, Bilbao and Valencia stock exchanges through the Stock Market Interconnection System.

The company's operations include marketing its own and licensed products and providing production, filling and packaging services to other companies. The site names three pillars of growth: a diversified portfolio of products protected by patents, a contract manufacturing (CDMO) business specialising in prefilled syringes and solid oral forms, and research and development. Its principal product is Bemiparin, a low-molecular-weight heparin developed in-house, which is present in many countries through alliances with international partners. The history page also mentions the Granada R&D centre and plant, an enoxaparin biosimilar, and a role in 2020 in the active substance manufacture and fill-finish of a coronavirus vaccine.

Those following Laboratorios Rovi stock usually watch sales of Bemiparin and the enoxaparin biosimilar, developments in contract manufacturing, regulatory steps for products such as Okedi and Risvan, and the company's announcements. On the Lzzo.com Laboratorios Rovi page, the price of the Madrid-listed shares appears with its observation time, together with a price history chart and technical indicators.